ChromaDex Co. (NASDAQ:CDXC) to Post Q2 2024 Earnings of ($0.03) Per Share, Roth Capital Forecasts

ChromaDex Co. (NASDAQ:CDXC) – Research analysts at Roth Capital reduced their Q2 2024 earnings per share (EPS) estimates for ChromaDex in a report issued on Thursday, May 9th. Roth Capital analyst S. Mcgowan now anticipates that the company will post earnings per share of ($0.03) for the quarter, down from their previous estimate of ($0.02). The consensus estimate for ChromaDex’s current full-year earnings is ($0.02) per share. Roth Capital also issued estimates for ChromaDex’s Q3 2024 earnings at $0.00 EPS.

Several other equities research analysts also recently commented on CDXC. HC Wainwright reiterated a “buy” rating and issued a $6.00 price objective on shares of ChromaDex in a report on Thursday. Roth Mkm lifted their price objective on ChromaDex from $4.25 to $6.00 and gave the company a “buy” rating in a research report on Tuesday, April 9th. Finally, StockNews.com started coverage on ChromaDex in a research report on Sunday, March 3rd. They set a “strong-buy” rating on the stock.

ChromaDex Price Performance

CDXC opened at $3.42 on Monday. The stock has a 50-day moving average price of $3.29 and a 200-day moving average price of $2.11. The firm has a market cap of $258.35 million, a PE ratio of -68.40 and a beta of 1.96. ChromaDex has a 1 year low of $1.25 and a 1 year high of $4.65.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the company. SG Americas Securities LLC acquired a new position in shares of ChromaDex in the first quarter valued at about $54,000. Acadian Asset Management LLC acquired a new position in ChromaDex during the first quarter worth $67,000. Silverberg Bernstein Capital Management LLC purchased a new stake in ChromaDex in the fourth quarter valued at $118,000. Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of ChromaDex by 121.9% in the 3rd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 83,031 shares of the company’s stock valued at $121,000 after buying an additional 45,618 shares during the period. Finally, Gabelli Funds LLC raised its holdings in shares of ChromaDex by 9.1% in the 3rd quarter. Gabelli Funds LLC now owns 180,000 shares of the company’s stock valued at $263,000 after buying an additional 15,000 shares during the period. Hedge funds and other institutional investors own 15.41% of the company’s stock.

About ChromaDex

ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.